• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

J&J Vision wins Japanese approval for first drug-releasing contact lens

March 25, 2021 By Sean Whooley

Johnson & Johnson Vision Acuvue TheravisionJohnson & Johnson Vision announced that it received approval in Japan for its Acuvue Theravision lens with Ketotifen.

The company touts the lens as the first and only vision-correcting contact lens that relieves allergic eye itch through drug delivery, according to a news release.

Japan’s Ministry of Health, Labour and Welfare (MHLW) approved the lens, which delivers ketotifen, an H1 histamine receptor antagonist for the prevention of itch associated with eye allergies.

“This approval marks another significant milestone in Johnson & Johnson Vision’s legacy of rethinking what’s possible with contact lenses, and bringing forward innovations to help eye care practitioners better meet the needs of their patients around the world,” J&J Vision global head of R&D Dr. Xiao-Yu Song said in the release. “Our goal at Johnson & Johnson Vision is to change the trajectory of eye health and we will continue to drive new innovation and technologies that correct, enhance, and restore people’s vision over their lifetimes.”

Johnson & Johnson Vision said the product is the first in what it calls an entirely new contact lens category that will improve the patient experience for those with allergic eye itch.

“Over 40 percent of people suffer from eye allergies, and of those, 80 percent feel frustrated when allergies interfere with contact lens wear,” J&J Vision director of clinical science Dr. Brian Pall said. “We’re proud to bring forward a new contact lens that simultaneously provides vision correction and relief of allergic eye itch, without the need for allergy eye drops.”

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Regulatory/Compliance Tagged With: Johnson & Johnson

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS